E-DRUG: Report of Rectal Artesunate Meeting, 19 February 2016
-------------------------------------------------------------------------------
Dear colleagues,
On 19 February 2016, stakeholders from 13 organizations spanning the field of malaria prevention and control, seven malaria-endemic countries in Africa (Democratic Republic of Congo, Burkina Faso, Malawi, Central African Republic, Kenya, Uganda and Zambia) and the WHO came together to discuss experiences, challenges and overcoming obstacles relating to the implementation of rectal artesunate (RAS) as a pre-referral intervention for the management of severe malaria in children.
The meeting was co-convened in Nairobi, Kenya by Medicines for Malaria Venture (MMV), the US President's Malaria Initiative (PMI), UNICEF and Médecins Sans Frontières (MSF).
A report of the RAS Stakeholder Meeting is available in English and French at
http://www.mmv.org/newsroom/publications/rectal-artesunate-stakeholders-meeting-report
It summarises the key issues relating to the adoption and implementation of RAS in malaria-affected regions and outlines recommended actions to speed-up access to this life-saving medicine.
* CHAI, CDC, IFRC, Malaria Consortium, MMV, MSF, PFSCM i+ solutions, PSI, Save the Children, UNICEF, UNITAID, USAID, US-PMI.
Best wishes,
Lizzie
Elizabeth Poll | Medicines for Malaria Venture
Communications Manager
T: +41 22 555 03 17 | M: +41 79 907 59 92
Email: polle@mmv.org